These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 27350294)

  • 1. Reference pricing with endogenous generic entry.
    Brekke KR; Canta C; Straume OR
    J Health Econ; 2016 Dec; 50():312-329. PubMed ID: 27350294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of European pharmaceutical price regulation on generic price competition: a review.
    Puig-Junoy J
    Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous versus exogenous generic reference pricing for pharmaceuticals.
    Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R
    Int J Health Econ Manag; 2017 Dec; 17(4):413-432. PubMed ID: 28508248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
    Kong Y
    Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do higher-priced generic medicines enjoy a competitive advantage under reference pricing?
    Puig-Junoy J
    Appl Health Econ Health Policy; 2012 Nov; 10(6):441-51. PubMed ID: 22900924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
    Hong SH; Shepherd MD; Scoones D; Wan TT
    J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pricing dynamics of anti-seizure medications in the U.S.
    Javarayee P; Mtchedlidze T; Snell W; Mahesha V; Meylor J; Shahrukh S; Pollock S; Sah J; Dong Y; Patel H
    Seizure; 2024 Nov; 122():26-33. PubMed ID: 39306895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
    Dickson SR; Kent T
    JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreasing utilization and increasing prices of brand-name oral contraceptive pills: Implications to societal costs and market competition.
    Zhang JX
    PLoS One; 2020; 15(6):e0234463. PubMed ID: 32525965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High prices for generics in Australia - more competition might help.
    Bulfone L
    Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. More cost-sharing, less cost? Evidence on reference price drugs.
    Herr A; Stühmeier T; Wenzel T
    Health Econ; 2023 Feb; 32(2):413-435. PubMed ID: 36415146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reference pricing of pharmaceuticals.
    Brekke KR; Königbauer I; Straume OR
    J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic script share and the price of brand-name drugs: the role of consumer choice.
    Rizzo JA; Zeckhauser R
    Int J Health Care Finance Econ; 2009 Sep; 9(3):291-316. PubMed ID: 19130220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are drug prices subject to creative destruction? Evidence from the US, 1997-2017.
    Lichtenberg FR
    Health Econ; 2021 Aug; 30(8):1910-1932. PubMed ID: 33987916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tiered co-payments, pricing, and demand in reference price markets for pharmaceuticals.
    Herr A; Suppliet M
    J Health Econ; 2017 Dec; 56():19-29. PubMed ID: 28964941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reforming the Swedish pharmaceuticals market: consequences for costs per defined daily dose.
    Bergman MA; Granlund D; Rudholm N
    Int J Health Econ Manag; 2016 Sep; 16(3):201-214. PubMed ID: 27878673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.